However, given the biased formation of the complex containing the truncated CDK4 in CRC, it may be feasible to achieve targeted therapy exclusively against CRC by designing inhibitors that specifically target the p27-CDK4-CCND1 complex in CRC or by identifying upstream splicing factors that regulate the splicing of CDK4 exon 2. Here, CCND1 is linked to colorectal carcinoma.